137 related articles for article (PubMed ID: 30411646)
1. Time for patient reported outcomes assessment in routine hematology practice: the case of chronic myeloid leukemia.
Efficace F; Cottone F
Expert Rev Hematol; 2019 Jan; 12(1):1-3. PubMed ID: 30411646
[No Abstract] [Full Text] [Related]
2. Cytogenetics in the management of "chronic myeloid leukemia": an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Roche-Lestienne C; Boudry-Labis E; Mozziconacci MJ
Ann Biol Clin (Paris); 2016 Oct; 74(5):511-515. PubMed ID: 27477825
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Rea D; Ame S; Berger M; Cayuela JM; Charbonnier A; Coiteux V; Cony-Makhoul P; Dubruille V; Dulucq S; Etienne G; Legros L; Nicolini F; Roche-Lestienne C; Escoffre-Barbe M; Gardembas M; Guerci-Bresler A; Johnson-Ansah H; Rigal-Huguet F; Rousselot P; Mahon FX;
Cancer; 2018 Jul; 124(14):2956-2963. PubMed ID: 29723417
[TBL] [Abstract][Full Text] [Related]
4. Another set of guidelines for chronic myeloid leukaemia.
Clark RE
Br J Haematol; 2020 Oct; 191(2):147-149. PubMed ID: 32712951
[No Abstract] [Full Text] [Related]
5. Research in the heart of hematology: chronic myeloid leukemia 2017.
Hehlmann R
Haematologica; 2017 Mar; 102(3):418-421. PubMed ID: 28250004
[No Abstract] [Full Text] [Related]
6. Philadelphia negative BCR-ABL positive chronic myeloid leukemia mimicking juvenile chronic myeloid leukemia in a 2-year-old child.
Mahon FX; Labouyrie E; Aurich-Costa J; Dastugue N; Micheau M; Bady C; Perel Y; Bilhou-Nabera C; Reiffers J; Bernard P
Leuk Lymphoma; 1997 Aug; 26(5-6):615-9. PubMed ID: 9389369
[TBL] [Abstract][Full Text] [Related]
7. Hematology clinic: chronic myelogenous leukemia.
Weber AA; Talpaz M
Hematology; 2013 Nov; 18(6):372-3. PubMed ID: 24129094
[No Abstract] [Full Text] [Related]
8. Ischaemic priapism as a presentation of chronic myeloid leukaemia.
Villegas Osorio JF; Corchuelo Maíllo C; Cuevas Palomino A; Medina López RA
Arch Esp Urol; 2014 Oct; 67(8):708-11. PubMed ID: 25306990
[TBL] [Abstract][Full Text] [Related]
9. Population-Based Testing and Treatment Characteristics for Chronic Myelogenous Leukemia.
Styles T; Wu M; Wilson R; Babcock F; Butterworth D; West DW; Richardson LC
J Registry Manag; 2016; 41(3):134-142. PubMed ID: 28121314
[TBL] [Abstract][Full Text] [Related]
10. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
Kantarjian HM; Mamolo CM; Gambacorti-Passerini C; Cortes JE; Brümmendorf TH; Su Y; Reisman AL; Shapiro M; Lipton JH
Cancer; 2018 Feb; 124(3):587-595. PubMed ID: 29072772
[TBL] [Abstract][Full Text] [Related]
11. Philadelphia chromosome-negative, bcr/abl-positive chronic myelogenous leukemia.
Inokuchi K; Dan K
J Nippon Med Sch; 2001 Aug; 68(4):292-3. PubMed ID: 11505275
[No Abstract] [Full Text] [Related]
12. [The usefulness of the bcr/abl rearrangement in the diagnosis and evolution of chronic myeloid leukemia].
González FA; Villegas A; Ferro MT; San Román C; Sáez I; López M; del Potro E; Alvarez A; Martínez R; Díaz Madiavilla J
Med Clin (Barc); 1993 Oct; 101(14):521-4. PubMed ID: 8231395
[TBL] [Abstract][Full Text] [Related]
13. [Malignant and premalignant processes of myeloid systems. Guidelines of the Professional College of Hematology].
Orv Hetil; 1994 Dec; 135(50):2775-6. PubMed ID: 7838512
[No Abstract] [Full Text] [Related]
14. Are chronic myeloid leukemia patients ready to stop long-term treatment?
Breccia M; Efficace F
Leuk Lymphoma; 2017 Dec; 58(12):2976-2978. PubMed ID: 28535695
[No Abstract] [Full Text] [Related]
15. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
Jiang Q; Wang HB; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
[TBL] [Abstract][Full Text] [Related]
16. [Differential diagnosis of chronic myeloid leukemia and the related disorders].
Ashida T; Kanamaru A
Nihon Rinsho; 2001 Dec; 59(12):2358-62. PubMed ID: 11766339
[TBL] [Abstract][Full Text] [Related]
17. How could patient reported outcomes improve patient management in chronic myeloid leukemia?
De Marchi F; Medeot M; Fanin R; Tiribelli M
Expert Rev Hematol; 2017 Jan; 10(1):9-14. PubMed ID: 27858461
[TBL] [Abstract][Full Text] [Related]
18. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
Colla S; Sammarelli G; Voltolini S; Crugnola M; Sebastio P; Giuliani N
Haematologica; 2004 May; 89(5):611-3. PubMed ID: 15136228
[TBL] [Abstract][Full Text] [Related]
19. A novel large-sized BCR-ABL transcript in a case of chronic myeloid leukaemia characterised by a favourable clinical course.
De Matteis G; Veneri D; Aprili F; Benati M; Paviati E; Guidi GC; Pizzolo G; Tecchio C
Ann Hematol; 2013 Mar; 92(3):413-5. PubMed ID: 23053185
[No Abstract] [Full Text] [Related]
20. BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib.
Maël H; Audrey B; Evelyne CB; Pierre-Yves D; Kaddour C; Gilles S; Arnaud P
Ann Hematol; 2017 Feb; 96(2):335-336. PubMed ID: 27761606
[No Abstract] [Full Text] [Related]
[Next] [New Search]
